| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/15412555.2010.496817 |
| P953 | full work available at URL | https://www.tandfonline.com/doi/pdf/10.3109/15412555.2010.496817?needAccess=true |
| http://www.tandfonline.com/doi/pdf/10.3109/15412555.2010.496817 | ||
| P698 | PubMed publication ID | 20673037 |
| P2093 | author name string | Juan José Soler-Cataluña | |
| Roberto Rodriguez-Roisin | |||
| P2860 | cites work | Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease | Q29618681 |
| Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease | Q34180835 | ||
| Impact of preventing exacerbations on deterioration of health status in COPD. | Q34548347 | ||
| Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? | Q34777791 | ||
| Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study | Q79902627 | ||
| A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease | Q79975575 | ||
| Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease | Q80264024 | ||
| Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors | Q82892213 | ||
| ??? | Q57219091 | ||
| A 4-year trial of tiotropium in chronic obstructive pulmonary disease | Q34845834 | ||
| COPD exacerbations: definitions and classifications. | Q35149042 | ||
| Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations | Q35533637 | ||
| Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease | Q35534824 | ||
| Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations | Q35535368 | ||
| Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. | Q35535679 | ||
| Time course of recovery of health status following an infective exacerbation of chronic bronchitis | Q35536058 | ||
| Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. | Q35537270 | ||
| COPD exacerbations .1: Epidemiology | Q36183861 | ||
| Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? | Q36203170 | ||
| Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. | Q36912026 | ||
| Polymorphic variation in surfactant protein B is associated with COPD exacerbations. | Q37387050 | ||
| Impact on patients' health status following early identification of a COPD exacerbation | Q40181033 | ||
| Costs of chronic bronchitis and COPD: a 1-year follow-up study | Q40601070 | ||
| The economic burden of COPD. | Q40778466 | ||
| Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients | Q41998751 | ||
| Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial | Q42612610 | ||
| Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways | Q43578013 | ||
| Risk factors of emergency care and admissions in COPD patients with high consumption of health resources | Q44835775 | ||
| Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease | Q44959741 | ||
| Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. | Q44994420 | ||
| Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. | Q46150950 | ||
| Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers | Q46417535 | ||
| Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study | Q46568144 | ||
| Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort | Q46874382 | ||
| Optimized dialysis and protease inhibition of sputum dithiothreitol supernatants | Q46930197 | ||
| Epidemiological relationships between the common cold and exacerbation frequency in COPD. | Q47698479 | ||
| Airway and systemic inflammation and decline in lung function in patients with COPD. | Q47707074 | ||
| Exacerbations and time spent outdoors in chronic obstructive pulmonary disease | Q47885117 | ||
| Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. | Q50680798 | ||
| Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. | Q50792764 | ||
| Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. | Q51659807 | ||
| Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. | Q51672311 | ||
| The costs of exacerbations in chronic obstructive pulmonary disease (COPD). | Q51703317 | ||
| Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. | Q52163132 | ||
| Impact of COPD exacerbations on patient-centered outcomes. | Q53201568 | ||
| Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. | Q53577143 | ||
| Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations | Q58877199 | ||
| Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease | Q62111232 | ||
| Relationship between depression and exacerbations in COPD | Q62111233 | ||
| Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) | Q71718436 | ||
| Muscle weakness is related to utilization of health care resources in COPD patients | Q73094085 | ||
| Acute exacerbation of COPD: factors associated with poor treatment outcome | Q73538161 | ||
| Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease | Q73777945 | ||
| Inflammatory changes, recovery and recurrence at COPD exacerbation | Q79362620 | ||
| Risk indexes for exacerbations and hospitalizations due to COPD | Q79546220 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 276-284 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | COPD: Journal of Chronic Obstructive Pulmonary Disease | Q5013430 |
| P1476 | title | Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious? | |
| Frequent Chronic Obstructive Pulmonary Disease Exacerbators: How Much Real, How Much Fictitious? | |||
| P478 | volume | 7 |
| Q63979042 | Chronic Obstructive Pulmonary Disease |
| Q38282787 | Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management |
| Q36434316 | Clinical Features according to the Frequency of Acute Exacerbation in COPD |
| Q41144316 | Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations |
| Q38116939 | Early identification of exacerbations in patients with chronic obstructive pulmonary disease |
| Q45031378 | Frequent exacerbators--a distinct phenotype of severe asthma |
| Q37626464 | Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD. |
| Q28596774 | Prevention of COPD exacerbations: medications and other controversies |
| Q41400495 | Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns |
| Q51159286 | Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. |
| Q57955719 | The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD) - why and what? |
| Q34742591 | The concept of control of COPD in clinical practice. |
| Q37732387 | The recent advances of phenotypes in acute exacerbations of COPD. |
| Q38095562 | What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease? |
| Q84148872 | [Impact of exacerbations on the clinical course of chronic obstructive pulmonary disease] |
| Q83401074 | [Multidimensional impact of COPD exacerbations] |
Search more.